FDA — authorised 3 August 2017
- Application: NDA209401
- Marketing authorisation holder: JAZZ PHARMS THERAP
- Status: supplemented
FDA authorised Vyxeos on 3 August 2017
Yes. FDA authorised it on 3 August 2017; FDA has authorised it.
JAZZ PHARMS THERAP holds the US marketing authorisation.